Sugi Predict

Sugi Predict / Compounds / SCHEMBL10075487

SCHEMBL10075487

SCHEMBL10075487

CC(=O)N1CCN(C2CCCCC2)CC1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.58
▸ HSD17B10 Q99714 1/20 0.58
▸ PHGDH O43175 1/20 0.53
▸ MGLL Q99685 1/20 0.53
▸ KCNH2 Q12809 2/20 0.51
▸ HRH3 Q9Y5N1 2/20 0.51
▸ KDM4E B2RXH2 3/20 0.50
▸ EPHX2 P34913 2/20 0.50
▸ ALDH1A1 P00352 2/20 0.50
▸ EPHX1 P07099 1/20 0.50
▸ HPGD P15428 1/20 0.50
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ L3MBTL3 Q96JM7 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ SIGMAR1 Q99720 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13453747 1.00 POLB (0.58) POLBHSD17B10PHGDHMGLLKCNH2
SCHEMBL13088457 1.00 POLB (0.58) POLBHSD17B10PHGDHMGLLKCNH2
SCHEMBL13088446 0.98 POLB (0.55) POLBHSD17B10PHGDHMGLLKCNH2
SCHEMBL4550241 0.94 POLB (0.50) POLBHSD17B10PHGDHMGLLKCNH2
SCHEMBL15508283 0.89 CYP1A2 (0.52) POLBHSD17B10KCNH2HRH3KDM4E
SCHEMBL13627077 0.88 HRH3 (0.48) POLBHSD17B10HRH3L3MBTL3L3MBTL1
SCHEMBL18711627 0.86 CYP1A2 (0.45) POLBHSD17B10KCNH2HRH3EPHX2
SCHEMBL3765276 0.85 SIGMAR1 (0.52) POLBHSD17B10PHGDHMGLLHRH3
SCHEMBL23182433 0.85 TP53 (0.48) POLBHSD17B10PHGDHMGLLHRH3
SCHEMBL4669864 0.83 L3MBTL3 (0.58) KDM4EEPHX2ALDH1A1EPHX1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021062246-A1 CRF RECEPTOR ANTAGONISTS AND METHODS OF USE NEUROCRINE BIOSCIENCES, INC. (US) 2021-04-01 — — WO disclosed
EP-2403878-B1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 SQUIBB & SONS LLC (US) 2017-06-14 — — EP disclosed
US-8563559-B2 Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2013-10-22 — — US disclosed
US-20130156788-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 OXFORD BIOTHERAPEUTICS LTD (GB) 2013-06-20 — — US disclosed
US-8420084-B2 Fully human antibodies specific to CADM1 MEDAREX, INC. (US) 2013-04-16 — — US disclosed
US-20120093826-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 OXFORD BIOTHERAPEUTICS LTD (GB) 2012-04-19 — — US disclosed
US-20120027782-A1 MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-02 — — US disclosed
US-20110085970-A1 ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE BRISTOL-MYERS SQUIBB COMPANY 2011-04-14 — — US disclosed
US-20110020329-A1 CONJUGATES OF ANTI-RG-1 ANTIBODIES BRISTOL-MYERS SQUIBB COMPANY 2011-01-27 — — US disclosed
US-7671069-B2 Tricyclic, heteroaromatic compounds modulating CXCR4 and/ or CXCR7 CHEMOCENTRYX, INC. (US) 2010-03-02 — — US disclosed
US-20090170835-A1 ISOINDOLINE DERIVATIVES MARUISHI PHARMACEUTICAL CO., LTD. 2009-07-02 — — US disclosed
US-20090162372-A1 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE MEDAREX, INC. (US) 2009-06-25 — — US disclosed
US-7521451-B2 Isoindoline derivative MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2009-04-21 — — US disclosed
EP-1956010-A1 Bicyclical heterocycles, medicines containing these compounds, their application and method for their production Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2008-08-13 — — EP disclosed
US-20080021042-A1 Composition For Controlling Neuropathic Pain MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 — — US disclosed
US-20080021042-A1 Composition For Controlling Neuropathic Pain MARUISHI PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 — — US disclosed
EP-1749817-A1 NEUROGENIC PAIN CONTROL AGENT COMPOSITION Maruishi Pharmaceutical Co., Ltd. (JP) 2007-02-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090162372-A1 FIBRONECTIN ED-B ANTIBODIES, CONJUGATES THEREOF, AND METHODS OF USE FN1, EDNRB, EDF1 POLB 3600/4885HSD17B10 4045/4885PHGDH 4838/4885
US-20110085970-A1 ANTI-B7H4 MONOCLONAL ANTIBODY-DRUG CONJUGATE AND METHODS OF USE CD2BP2, CD274, CD22 POLB 2133/4885HSD17B10 3632/4885PHGDH 1893/4885
US-20120093826-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 FCGR1A, FCGR2A, FCGR3B POLB 1443/4885HSD17B10 4531/4885PHGDH 3575/4885
US-20130156788-A1 FULLY HUMAN ANTIBODIES SPECIFIC TO CADM1 FCGR1A, FCGR2A, FCGR3B POLB 1443/4885HSD17B10 4531/4885PHGDH 3575/4885
US-20110020329-A1 CONJUGATES OF ANTI-RG-1 ANTIBODIES GDI1, ARFGAP1, GLG1 POLB 3724/4885HSD17B10 4456/4885PHGDH 2663/4885
US-20080021042-A1 Composition For Controlling Neuropathic Pain GAP43, SCN10A, SCN2A POLB 4413/4885HSD17B10 3139/4885PHGDH 991/4885
US-20120027782-A1 MONOCLONAL ANTIBODY PARTNER MOLECULE CONJUGATES DIRECTED TO PROTEIN TYROSINE KINASE 7 (PTK7) PTK2, PTK2B, LTK POLB 3824/4885HSD17B10 3401/4885PHGDH 2885/4885
US-20090170835-A1 ISOINDOLINE DERIVATIVES OPRD1, OPRK1, OPRL1 POLB 3074/4885HSD17B10 2474/4885PHGDH 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.